Navigation Links
Arcturus Therapeutics Announces Collaboration with Takeda Pharmaceuticals to Develop RNA-based Therapeutics for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Date:12/6/2016

SAN DIEGO, Dec. 6, 2016 /PRNewswire/ -- Arcturus Therapeutics, Inc. ("Arcturus" or the "Company"), a leading RNA medicines company, announced today that it entered into collaboration with Takeda Pharmaceutical Company Limited, to develop RNA-based therapeutics for the treatment of NASH and other gastrointestinal (GI) related disorders, utilizing Arcturus' wholly-owned therapeutic delivery platform LUNAR™ and UNA Oligomer chemistry. The financial terms were not disclosed.

"Given Takeda's long-standing commitment to and expertise in GI disorders, we are confident we have found an ideal partner to accelerate and maximize the potential of our LUNAR and UNA technology platforms toward the development of novel RNA therapeutics for the treatment of NASH," said Dr. Pad Chivukula, CSO & COO of Arcturus Therapeutics, Inc. "This agreement underscores Arcturus' ability to rapidly discover, design and optimize RNA medicines in areas of unmet need." 

About Arcturus Therapeutics, Inc.   

Founded in 2013 and based in San Diego, Arcturus Therapeutics, Inc. is an RNA medicines company with enabling technologies — UNA Oligomer chemistry and LUNAR™ nanoparticle delivery. Arcturus' versatile RNA therapeutics platform can be applied toward all types of RNA medicines including small interfering RNA, messenger RNA, antisense RNA, microRNA and gene editing therapeutics. The company owns LUNAR™ nanoparticle delivery and unlocked nucleomonomer agent (UNA) technology including UNA Oligomers™, which are covered by its patent portfolio (77 patents and patent applications, issued in the U.S., Europe, Japan and other countries). Arcturus' proprietary UNA technology can be used to target any gene in the human genome, as well as viral genes, and other species for therapeutic purposes. The Company's commitment to the development of novel RNA therapeutics has led to collaborations and license agreements with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and Ultragenyx Pharmaceutical, Inc. For more information, visit www.ArcturusRx.com.

Logo - http://photos.prnewswire.com/prnh/20130531/MM24393LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/arcturus-therapeutics-announces-collaboration-with-takeda-pharmaceuticals-to-develop-rna-based-therapeutics-for-the-treatment-of-nonalcoholic-steatohepatitis-nash-300373830.html


'/>"/>
SOURCE Arcturus Therapeutics
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Arcturus Therapeutics Receives Intent to Grant Notice from the European Patent Office for their Unlocked Nucleomonomer Agent (UNA) Technology
2. Arcturus Therapeutics Announces the Appointment of Drew Weissman M.D., Ph.D. to the Scientific Advisory Board
3. Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines for Defined Indications
4. Arcturus Therapeutics to Present at the Genetic Rx Boston Biotech Conference
5. Arcturus Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
6. Arcturus Therapeutics, Inc. Announces an RNAi Therapeutic Targeting Transthyretin-mediated Amyloidosis as its Flagship Program
7. Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina Biotech
8. Viking Therapeutics Receives Orphan Drug Designation for VK0214 from the U.S. Food and Drug Administration for the Treatment of X-Linked Adrenoleukodystrophy
9. Mission Therapeutics Appoints Colin Goddard as Chairman
10. Research Reports Initiation on Healthcare Stocks -- NuVasive, Smith & Nephew, Nxstage Medical, and Cesca Therapeutics
11. Research Reports Coverage on Biotech Stocks -- Celldex Therapeutics, Amicus Therapeutics, Navidea Biopharma, and Concordia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2019)... , ... February 13, 2019 , ... ... with Vision Source ® as the recipients for the ‘Empower Your Care ... awards, which were announced at the 2019 HIMSS Annual Conference and Exhibition ...
(Date:2/13/2019)... Calif. (PRWEB) , ... February 13, 2019 , ... According ... or female) now has a BMI of 26.5, which is considered overweight (the healthy ... the start of the 1980’s into the new millennium, and now news outlets are ...
(Date:2/13/2019)... ... 2019 , ... Abu Dhabi Health Data Services, a new ... Department of Health-Abu Dhabi (DoH) and Injazat Data Systems, a subsidiary of Mubadala ... centralized platform to streamline healthcare connectivity for the Emirate. The system is known ...
Breaking Medicine Technology:
(Date:2/13/2019)... ... February 13, 2019 , ... Dr. Christie ... Haute Beauty network. , The Haute Beauty Network, well known for their ... leading Aesthetic surgeon and our newest addition to the Haute Living partnership. ...
(Date:2/12/2019)... ... February 12, 2019 , ... ... from FDAnews and Ombu Enterprises**, Feb. 19-20, 2019, Atlanta, GA , https://www.fdanews.com/mdriskmanagement ... for the Winds of Change on Jan. 22 , Risk management is just ...
(Date:2/12/2019)... (PRWEB) , ... February 12, 2019 , ... Attorney ... an international educator on advancing standards in addiction treatment, has pledged to donate $1-million ... A Prescription for Liberating a Nation in Pain, to charities across America in 2019, ...
(Date:2/12/2019)... ... February 12, 2019 , ... ... to increase patient satisfaction, improve patient retention, and reduce patient outmigration for attendees ... 11-14. HIMSS provides Surgical Theater with a great venue to highlight the ...
(Date:2/11/2019)... ... February 11, 2019 , ... Z-Medica, LLC, a ... announced today the appointment of nationally recognized cardiothoracic surgeon and researcher, Vinod Thourani, ... Surgery at Georgetown University School of Medicine and the Chairman of Cardiac Surgery ...
Breaking Medicine News(10 mins):